🔗 Share this article

While the United States undertakes unprecedented adjustments to its vaccine schedules, a particular individual has emerged unexpectedly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by questioning COVID-19 shots in the pandemic and has concentrated on potential fatalities following COVID-19 immunization in her recent time at the Food and Drug Administration.

Proposed Overhauls to Childhood Immunization Schedule

Health officials were set to reveal major revisions to the pediatric vaccine schedule earlier this month, aligning the US with Denmark’s immunization schedule, sources say – a major change that would place the US out of step with many the world with little proof for public health gain. This reveal has been pushed back until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is set to speak at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the office this year.

A New Direction at the FDA

The acting appointment could signify a strengthened alliance between the drug and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it signals a increased emphasis upon dismantling previously authorized immunizations at the FDA.

The new acting director has repeatedly called for ending some pediatric immunization guidelines in the US to become more like Denmark's approach, a country with nationalized medicine and a citizenry about the population of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccines – traditionally the purview of Dr. Prasad, director of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Qualifications

Dr. Høeg has no apparent background in pharmaceutical research, regulation or leadership, which has been typical for past leaders of the biologics center. She has worked at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in leading a sizeable institution. She is not an expert in drug approvals.”

Past commissioners of CBER would “grasp laws and regulations and the research of medication creation”, commented a former acting FDA commissioner. “Clearly, she lacks the kind of background that former directors who led the center have had.”

The drug center has an vast workload at the agency, Woodcock pointed out.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office approves numerous generic drugs. There is also a biosimilars program, non-prescription drug unit and more, and every single one must be supervised,” Dr. Woodcock explained. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Additionally, a significant management element to the job, which manages in excess of 5,000 employees. “It’s a enormous leadership role, if you perform it correctly,” the former official added.

Response and Contentious Policies

In response to questions about Dr. Høeg's fitness for the role and whether this assignment signifies increased cooperation among regulatory chiefs on vaccines, a representative stated that the “inquiries are based on flawed presumptions”.

“This background aligns with the responsibilities of her job,” the official said, pointing to the months Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a disputed rapid drug-approval program that apparently concerned her preceding directors. “How are these medications being chosen for this voucher program? Who takes the decisions?” Howard said. “There is a lot of confidentiality going on at the regulatory body right now.”

Overall, he stated, “the agency seems to be moving towards more relaxed regulations of all drugs, aside from immunizations.”

Established History on Vaccines

With vaccines, Dr. Høeg has a clearer, if concerning, history, critics have noted. She released a research paper using non-validated volunteer-provided data to assess the frequency of myocarditis following COVID-19 vaccination. She advised the state of Florida top health official Dr. Joseph Ladapo, who was said to have altered data to indicate Covid vaccinations are more dangerous than they are.

Among her “desired changes” for the incoming administration encompassed revising rules for new vaccines and ending “unnecessary” vaccines, she said after the election on a podcast. At the FDA, Dr. Høeg has allegedly suggested preventing teenage boys from getting COVID-19 vaccinations.

“She’s an complete dogmatist who starts off with her preconceived notions and works backwards to accommodate the evidence in a very disingenuous, dishonest way,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Høeg became part of other dissenters, {like|